- Atomoxetine (Strattera®)
- Citalopram (Celexa®)
- Coenzyme Q-10 - PREQUEL
- Creatine - PRECREST
- Ethyl-EPA (Miraxion)
- Memantine (Namenda®)
- Minocycline (Minocin®)
- Tetrabenazine (Nitoman®, Xenazine®)
Clinical Trial Background by Huntington Study Group (HSG)
Clinical Trial Background by NIH ClinicalTrials.gov
List of Clinical Trials by NIH ClinicalTrials.gov
Trial results (press release)
Trial information at NIH ClincalTrials.gov
Trial status: This phase III clinical trial is complete, with preliminary negative results at six months.
Trial name: TREND-HD
FDA phase: Phase III
Sponsor: Amarin Corporation
Trial design: A 6-month, double-blind, randomized, placebo-controlled trial, studying 316 HD patients over the age of 35 who have early stages of HD. For the first 6 months, participants were divided into two groups, one taking 2 grams of the drug every day, and the other group taking placebo. During the second follow-up 6 months, all participants took the study drug.
Outcome measures: Total motor comparison after 6 months of drug treatment; also, measures of cognitive and functional capacity.
Location: 43 sites
Results: No motor or other improvement was seen at the end of the six month trial.